Master the GLP-1 Frontier
A Clinical Boot Camp for General Practitioners —
15 July 2026 | Metropolitan Hotel, Dubai
Empower your practice with the clinical confidence to prescribe and manage GLP-1 and dual GIP/GLP-1 agonists safely. Organised by The Mighty Musketeers FZC in collaboration with MediFamily Polyclinic DSO — medifamilydubai.co | DHA Approved Category 1 CME Hours (Applied for)
What You Will Learn
Move beyond surface-level familiarity with these agents. This intensive boot camp delivers a rigorous, mechanistic, and clinically actionable curriculum — from incretin physiology to long-term weight maintenance strategies.
Incretin Physiology & Receptor Pharmacology
Gain command of GLP-1 receptor biology and understand the mechanistic distinctions between GLP-1 mono-agonists (semaglutide) and dual GIP/GLP-1 receptor agonists (tirzepatide). Build the science that underpins confident prescribing.
Patient Safety & Evidence-Based Titration
Master structured titration protocols and learn to identify absolute contraindications — including medullary thyroid carcinoma, MEN2, and acute pancreatitis. Reduce adverse event risk through validated clinical decision frameworks.
Weight Maintenance Without Reversal
Gain clinical insight into long-term management strategies that sustain target weight loss outcomes. Learn how to support patients through maintenance phases, prevent weight regain, and optimise cardiometabolic risk reduction over time.
Interactive Case Study Sessions
Participate in real-world case discussions that simulate clinical decision-making under pressure. Leave with the judgement and decision-making memory to act from day one — not after months of hesitation. These sessions are designed to build reflexive clinical confidence across the spectrum of obesity, T2DM, and cardiometabolic risk management.
Who Should Attend?
This boot camp is designed for clinicians encountering patients asking about semaglutide, tirzepatide, and related agents.
- GPs seeking structured CME in metabolic medicine
- Clinicians new to incretin-based therapies
- Practitioners managing obesity, T2DM, and cardiometabolic risk
- Any physician seeking DHA Category 1 credit hours
Faculty Profiles
Dr. Idrees Mubarik — Senior Specialist Endocrinologist | clinician with expertise in metabolic medicine and endocrine pharmacology. View Profile
Dr. Syed Hasnain Ali Johr — Senior Specialist Family Physician and a clinical lead at MediFamily Polyclinic DSO, with deep experience in family and metabolic medicine. View Profile
Dr. Sulaiman Ahmed — Primary care Clinician and Healthcare leader with a strong track record in UAE-based practice and medical education. View Profile
Event Details & Registration
📅 Date
15 July 2026
9am to 4pm (lunch & tea breaks additional)
📍 Venue
Metropolitan Hotel, Dubai
Sheikh Zayed Road, Exit 41 — Al Thanya St, Dubai
🏅 Accreditation
DHA Approved Category 1 CME Hours (Applied for)
🏢 Organised By
The Mighty Musketeers FZC in collaboration with MediFamily Polyclinic DSO
Registration Fees
Individual: AED 1,700 per physician
Group of 3: AED 1300 per physician (20% subsidised discount applied)
Group registration is a cost-effective option for clinic teams and polyclinic departments looking to upskill together. Contact us via WhatsApp to arrange group bookings.
Secure Your Place Today
Seats are limited. Complete the registration form to confirm your attendance. For queries, group bookings, or sponsorship enquiries, reach the organising team directly via WhatsApp.
📧 For further information: WhatsApp the organising team or visit medifamilydubai.co
Meet the Faculty
Dr. Idrees Mubarik
Consultant Endocrinologist (Head of Department), Saudi German Hospital Dubai
Course Trainer
Qualifications: MBBS, MD (Internal Medicine), D.M. (Endocrinology)
Experience: 12+ years in endocrinology
Languages: English, Hindi, Kashmiri, Urdu
Areas of Interest: Diabetes Mellitus, Thyroid Diseases (including malignancies), PCOS, Pituitary Disease, Adrenal Disorders, Ovarian and Testicular Diseases
Dr. Idrees Mubarik brings over 12 years of specialist endocrinology experience to the GLP-1 Boot Camp, with a particular focus on the pharmacological management of obesity and metabolic disease.
As Head of Endocrinology at Saudi German Hospital Dubai, he has extensive hands-on experience prescribing and titrating GLP-1 receptor agonists — including semaglutide and tirzepatide — for patients with Type 2 diabetes, PCOS, and complex cardiometabolic risk profiles. His clinical approach integrates receptor-level pharmacology with practical, patient-centred weight loss strategies, making him uniquely positioned to guide GPs through the evidence base and real-world application of these transformative agents.
Dr. Syed Hasnain Ali Johr
Specialist Family Medicine | CEO & Director, MediFamily Polyclinic DSO
Course Trainer
Qualifications: MBBS, MRCGP (UK), MAAFP (US)
Experience: 23+ years in Family Medicine
Clinical Expertise: Diabetes, hypertension, obesity & weight management, hormonal & thyroid disorders, chronic disease management, metabolic medicine
Dr. Syed Hasnain Ali Johr is one of Dubai's most experienced Family Medicine Specialists, with 23 years of frontline clinical practice managing obesity, metabolic syndrome, and weight-related comorbidities. Holding both the MRCGP (UK) and MAAFP (US).
He brings an internationally grounded perspective to GLP-1 prescribing within the primary care setting — where the majority of weight management journeys begin. At MediFamily Polyclinic DSO, Dr. Johr has guided numerous patients through structured GLP-1 therapy programmes, combining pharmacological intervention with lifestyle medicine to achieve durable, clinically meaningful weight loss outcomes.
Dr. Sulaiman Ahmad
Medical Director | Family Physician
Course Coordinator
Qualifications: MBBS · M.Phil Pathology (Haematology) · PG Cert Family Medicine · CHPE · Certified AI Healthcare Specialist, Johns Hopkins University USA.
Fellow of International Diabetes Federation, Member American Diabetes Association (ADA & American Academy of Family Physicians (AAFP)
Experience: 25+ years in Cardiometabolic Medicine | Medical Director, Access Clinic Al Quoz, Dubai.
Clinical Expertise: Primary Care, Metabolic Health, Diabetes Remission support, Obesity & Weight Management, Executive Health, Cardiometabolic Medicine.
Dr. Sulaiman Ahmad is a Primary care Physician with special interest in Diabetes Remission with over 25 years of clinical experience. He serves as Medical Director across Dubai and Karachi, and is a Certified AI Healthcare doctor from Johns Hopkins University, USA. He coordinates the GLP-1 Boot Camp faculty with clinical expertise in metabolic medicine, diabetes remission, and evidence-based weight management — bringing a whole-person, collaborative approach to every patient interaction.
GLP-1 Medications: A Comprehensive Course for GPs
A six-module Boot Camp curriculum designed to equip General Practitioners with evidence-based clinical knowledge, practical prescribing strategies, and patient-centered care frameworks for GLP-1 receptor agonist therapy.
Course Overview
The GLP-1 Boot Camp is a structured professional development program built specifically for General Practitioners. Across six comprehensive modules, participants gain a deep, clinically relevant understanding of GLP-1 receptor agonists — from foundational pharmacology through to long-term patient management and medico-legal considerations.
Each module is carefully scaffolded to build on the last, ensuring GPs leave with not just theoretical knowledge but actionable, practical skills they can apply immediately in their consultations. Whether you are new to prescribing GLP-1 medications or looking to refine your approach, this course delivers the depth and nuance required for safe, confident, and effective practice.
Core Modules
Comprehensive, scaffolded learning units
Key Drug Classes
Semaglutide & Tirzepatide in focus
Clinical Domains
Obesity, T2DM & cardiovascular risk
Integrated Framework
Medico-legal, ethical & lifestyle focus
Module 1: Foundations of GLP-1 Therapy
This foundational module introduces participants to the science behind GLP-1 receptor agonists, providing the essential pharmacological and clinical context required for all subsequent learning. Participants explore the gut-brain axis, insulin secretion pathways, and the pivotal role GLP-1 plays in glucose homeostasis and appetite regulation.
Creator Objectives
- Understand the mechanism of action of GLP-1 receptor agonists
- Differentiate between available agents (semaglutide, liraglutide, tirzepatide)
- Identify approved indications: Type 2 diabetes and obesity management
- Recognise contraindications and key safety signals
Learning Outcomes
- Articulate how GLP-1 agonists reduce HbA1c and promote weight loss
- Select appropriate agents based on patient profile and indication
- Apply foundational pharmacology to real-world prescribing decisions
- Communicate drug mechanisms clearly to patients and carers
Module 2: Patient Selection & Clinical Assessment
With a firm pharmacological foundation established, Module 2 shifts focus to the clinical encounter — specifically, how GPs identify and assess patients who are appropriate candidates for GLP-1 therapy. This module emphasises a structured, patient-centred assessment process that accounts for medical history, metabolic risk, comorbidities, and individual patient goals.
Identifying Eligible Patients
Criteria for initiating GLP-1 therapy in T2DM and obesity, including BMI thresholds, HbA1c targets, and cardiovascular risk stratification.
Baseline Clinical Workup
Essential pre-prescribing investigations: renal function, thyroid screening, hepatic markers, and contraindication screening before initiating therapy.
Shared Decision Making
Frameworks for engaging patients in informed consent discussions, including realistic expectations around weight loss, side effects, and duration of treatment.
Module 3: Prescribing, Dosing & Titration
Module 3 is the prescribing practicum of the Boot Camp. Participants learn the precise dosing schedules, titration protocols, and administration techniques for the most commonly used GLP-1 agents in Australian general practice. Special attention is given to managing the dose-escalation phase, where tolerability is often tested and adherence is most at risk.
Initiation Dose
Start at the lowest recommended dose to minimise GI side effects. For semaglutide (Ozempic): 0.25 mg weekly for the first 4 weeks.
Titration Phase
Escalate dose every 4 weeks based on tolerability and glycaemic or weight response. Monitor for nausea, vomiting, and injection site reactions throughout.
Maintenance Dose
Achieve target maintenance dose (e.g. 1 mg or 2 mg semaglutide weekly) tailored to clinical response, patient goals, and tolerability profile.
Monitoring & Review
Schedule regular follow-up to assess efficacy, reinforce lifestyle modifications, and screen for emerging adverse effects or contraindication triggers.
Module 4: Managing Side Effects & Adverse Events
One of the most clinically demanding aspects of GLP-1 prescribing is managing the side effect profile that frequently accompanies therapy — particularly during dose escalation. Module 4 equips GPs with evidence-based, practical tools to anticipate, prevent, and manage common and rare adverse effects, keeping patients on therapy and minimising unnecessary cessation.
Common Side Effects
GI Disturbance
Nausea, vomiting, diarrhoea, and constipation — most prominent during titration. Managed with dietary adjustments, slow escalation, and patient education.
Injection Site Reactions
Redness, bruising, or nodule formation. Rotating injection sites and correct technique reduce incidence significantly.
Hypoglycaemia Risk
Particularly when combined with sulfonylureas or insulin. Dose reduction strategies and patient monitoring protocols are covered in depth.
Rare but Serious Events
Pancreatitis
Recognising early symptoms, appropriate cessation protocols, and when to escalate to specialist care or emergency services.
Thyroid C-Cell Concerns
Evidence review on medullary thyroid carcinoma risk, contraindication in MEN2, and informed consent documentation requirements.
Gallbladder Disease
Increased cholelithiasis risk with rapid weight loss. Surveillance recommendations and referral pathways for symptomatic patients.
Module 5: Lifestyle Integration & Long-Term Management
GLP-1 therapy is most effective when embedded within a comprehensive, multidisciplinary approach to metabolic health. Module 5 explores how GPs can integrate pharmacotherapy with structured lifestyle interventions — nutrition, physical activity, behavioural change, and psychological support — to maximise long-term outcomes for patients with obesity and Type 2 diabetes.
Nutrition Frameworks
Evidence-based dietary patterns that complement GLP-1 therapy, including low-glycaemic index approaches, protein optimisation, and hydration strategies to manage GI side effects.
Physical Activity Prescription
RACGP-aligned exercise recommendations tailored to patients with obesity and mobility limitations. How to integrate exercise referral into the GLP-1 management plan.
Behavioural & Psychological Support
Addressing weight stigma, disordered eating patterns, and motivation. Referral pathways to psychologists, dietitians, and multidisciplinary obesity clinics.
Long-Term Monitoring Plans
Structured review cadence for sustained therapy: glycaemic targets, weight plateau management, medication continuation versus cessation decisions, and relapse prevention.
Module 6: Medico-Legal, Ethical & Practical Considerations
The final module addresses the growing medico-legal landscape surrounding GLP-1 prescribing in Australia — an area of increasing relevance as off-label use, compounded preparations, and telehealth prescribing proliferate. GPs will develop the frameworks needed to prescribe confidently, document thoroughly, and navigate complex ethical terrain.
📋 Informed Consent
Comprehensive consent documentation for GLP-1 therapy, including off-label use disclosure, realistic expectation setting, and patient rights in shared decision making.
⚖️ PBS & Regulatory Context
Current PBS listings for semaglutide and tirzepatide, private prescribing pathways, TGA requirements, and navigating compounded GLP-1 preparations safely.
🏥 Clinical Documentation
Best-practice medical record standards: what to document at initiation, every review, and at cessation to protect both patient and practitioner in medico-legal scenarios.
🤝 Ethical Prescribing
Managing patient demand versus clinical appropriateness, conflicts of interest in commercial weight loss settings, and equitable access considerations across patient populations.
Join the GLP-1 Boot Camp
Designed for General Practitioners committed to excellence in metabolic and obesity medicine, the GP's Boot Camp delivers a level of clinical depth and practical applicability that standalone CPD events rarely achieve. This is structured, purposeful learning — built for busy clinicians who demand real-world relevance.
For Attendees
Arrive prepared. Review the module overview above to understand the learning arc and identify areas where you want to deepen your knowledge. Each session is interactive — come with your clinical questions ready.
For Speakers
This curriculum map provides the bird's-eye view of how your module fits within the broader Boot Camp narrative. Align your content to the stated objectives and outcomes to ensure a cohesive, high-impact participant experience.
Master the GLP-1 Frontier